drugset / Trial / NCT00003858

Mitoxantrone Following Surgery in Treating Patients With Prostate Cancer at High Risk for Recurrence

NCT00003858

NaSingle-groupOpen-labelTreatment

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving chemotherapy after surgery may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of mitoxantrone given after surgery in treating patients who have prostate cancer that is at high risk for recurrence.

Timeline

Start
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Mitoxantrone Small molecule 17 mg/m2 Intravenous
Subject Mitoxantrone Small molecule 21 mg/m2 Intravenous

Indications